Earnings Summary

Aerie Pharmaceuticals Inc’s revenue jumped 23.25% since last year same period to $36.13Mn in the Q3 2022. On a quarterly growth basis, Aerie Pharmaceuticals Inc has generated 8.46% jump in its revenue since last 3-months.

Aerie Pharmaceuticals Inc’s net profit jumped 32.41% since last year same period to $-26.83Mn in the Q3 2022. On a quarterly growth basis, Aerie Pharmaceuticals Inc has generated -38.49% fall in its net profits since last 3-months.

Aerie Pharmaceuticals Inc’s net profit margin jumped 45.16% since last year same period to -74.25% in the Q3 2022. On a quarterly growth basis, Aerie Pharmaceuticals Inc has generated -27.68% fall in its net profit margins since last 3-months.

Aerie Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a -1.5% fall from last quarter’s estimates.

Aerie Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.45.

Aerie Pharmaceuticals Inc’s earning per share (EPS) jumped 52.24% since last year same period to -0.32 in the Q2 2022. This indicates that the Aerie Pharmaceuticals Inc has generated 52.24% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Aerie Pharmaceuticals Inc’s return on assets (ROA) stands at -0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Aerie Pharmaceuticals Inc’s return on equity (ROE) stands at -22.55.